The company developed a unique proprietary breath analysis solution called BreathBase. BreathBase consists of (i) the SpiroNose, a medical device that captures breath profiles in real-time, (ii) an online ML powered analysis platform and (iii) a large and highly valuable online reference database filled with >100.000 breath profiles and clinically validated data. This gives us an unparalleled edge over breath based and other diagnostic technologies.

Their cutting-edge solution is proven to be able to (early) diagnose multiple diseases, some of which up to two years sooner than current clinical practice. It can also predict which patient will respond to which medication, which enables precision medicine, leading to lower costs, and better outcomes for patients.The company collaborates with a global network of research partners and well-respected Key Opinion Leaders which resulted in a full research pipeline and significant scientific acknowledgement. A significant part of the clinical trials is being financed by third parties (e.g. clinical centers, pharmaceutical companies and health insurers), underpinning the recognition of the enormous potential of Breathomix’ Machine Learning-powered BreathBase solution.

Breathomix is on track to bring four applications of its breath analysis platform to the market in 2023, 2024 and 2025. The company can leverage its significant experience from the recent large-scale roll-out of its COVID-19 application. This makes Breathomix the only company in the world that has experience applying e-nose technology in clinical practice. Read more